Review Article
A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD
Table 2
Summary of upcoming therapeutic agents for NAFL/NASH.
| Treatment strategy | Medication | Comment |
| Bile Acid Receptors (FXR) | OCA | Has been shown to improve aminotransferases, insulin resistance, and NAS but can worsen lipid panel [84, 85] |
| PPAR alpha/delta agonist | Elafibranor | Can improve metabolic risk factors and lead to resolution of NASH [https://clinicaltrials.govāāNCT01694849] |
| Other agents | Cysteamine bitartrate, caspase inhibitor, and simtuzumab | Had promising results in phase 2 trials and some are still undergoing clinical trials |
|
|
FXR: farnesoid receptor; OCA: obeticholic acid.
|